Detalles de la búsqueda
1.
Adalimumab in Patients with Active Noninfectious Uveitis.
N Engl J Med
; 375(10): 932-43, 2016 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27602665
2.
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Ophthalmology
; 125(7): 1075-1087, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29429764
3.
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Lancet
; 388(10050): 1183-92, 2016 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27542302
4.
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Ophthalmology
; 124(12): 1799-1807, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28689898
5.
Adalimumab induces deep remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 12(3): 414-22.e5, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23856361
6.
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Gastroenterology
; 142(5): 1102-1111.e2, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22326435
7.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
JAMA Dermatol
; 156(6): 649-658, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32267471
8.
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Clin Pharmacokinet
; 58(6): 805-814, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30574672
9.
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.
Ocul Immunol Inflamm
; 27(1): 40-50, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30015528
10.
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
Dermatol Ther (Heidelb)
; 7(3): 365-381, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28815476
11.
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).
Am J Cardiol
; 90(12): 1300-6, 2002 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12480038
12.
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
J Crohns Colitis
; 8(11): 1407-16, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24874893
13.
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
J Gastroenterol
; 49(2): 283-94, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24363029
14.
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
J Crohns Colitis
; 7(1): 34-43, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22480772
15.
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Inflamm Bowel Dis
; 18(1): 1-9, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21351211
16.
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
J Crohns Colitis
; 6(2): 160-73, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22325170
Resultados
1 -
16
de 16
1
Próxima >
>>